報價延遲最少15分鐘:2025/07/18 16:32 EDT
盤後時段
|
||||
|
3.09 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.40/-0.41
|
|
企業價值
441.89M
|
| 資產負債 |
|
每股賬面淨值
0.80
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
850.00K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 16:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
